Drug Type Small molecule drug |
Synonyms LCI 139, LCI139 |
Action inhibitors |
Mechanism Aurora A inhibitors(Serine/threonine-protein kinase Aurora-A inhibitors), Aurora B inhibitors(Serine/threonine-protein kinase Aurora-B inhibitors), CDK4 inhibitors(Cyclin-dependent kinase 4 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Ewing Sarcoma | Preclinical | United States | 28 Apr 2025 | |
Non-Small Cell Lung Cancer | Preclinical | United States | 27 Apr 2025 | |
Endometrial Carcinoma | Preclinical | United States | 08 Apr 2024 | |
Mantle-Cell Lymphoma | Preclinical | United States | 12 Dec 2023 |